Related references
Note: Only part of the references are listed.Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2015)
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes
Zobair M. Younossi et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens
M. Stepanova et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C
Zobair Younossi et al.
DIGESTIVE AND LIVER DISEASE (2014)
Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Sofosbuvir-Containing Regimens
Zobair M. Younossi et al.
HEPATOLOGY (2014)
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Mark S. Sulkowski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C)
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2014)
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index
Amy A. Dan et al.
LIVER TRANSPLANTATION (2008)
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis
Herbert L. Bonkovsky et al.
JOURNAL OF HEPATOLOGY (2007)
Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment
BMR Spiegel et al.
HEPATOLOGY (2005)
Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels
RJ Willke et al.
CONTROLLED CLINICAL TRIALS (2004)
The estimation of a preference-based measure of health from the SF-36
J Brazier et al.
JOURNAL OF HEALTH ECONOMICS (2002)
The RAND-36 measure of health-related quality of life
RD Hays et al.
ANNALS OF MEDICINE (2001)
Share Paper
